Work

Natural microalgae-based oral zinc oxide-organic grid composite for intestinal infection control and complication mitigation

Year: 2026
Type: article
Abstract: The therapy of intestinal infections remains a considerable clinical challenge, primarily due to the prevalence of drug-resistance and the formation of biofilms lifestyle leading to recurrent episodes, as well as the destructive effects of traditional antimicrobial agents on the intestinal microbiota and barrier. Zinc ions have emerged as a promising therapeutic agent for gastrointestinal diseases. Scientific evidence shows that zinc plays key roles in addressing ulcers, sustaining the intestinal barrier, and balancing the gut microbiota. However, the application of zinc preparations in the treatment of gastrointestinal infection are restricted by issues such as limited antimicrobial effects, and short retention time. To address these limitations, we developed polydopamine-coated amorphous zinc oxide nanoparticles (ZnP) with superior antibacterial activity, and subsequently fabricated a zinc oxide-organic grid composite system derived from natural microalgae, designated as SP@ZnP. In Salmonella Typhimurium -induced enteritis, the villus-embedding effect of microalgae and the adhesiveness of polydopamine ensure effective targeting and retention of the system in the complex intestinal environment. The system exerts a strong inhibitory effect on planktonic bacteria and biofilm communities by inducing redox imbalance and disrupting bacterial metabolism. The released zinc ions and SP can also protect the tight junction proteins of intestinal epithelium layer and mucus layer, and restore the homeostasis of the gut microbiota. In addition, the protective effect of SP@ZnP on the mucosal barrier has been extended to the treatment of other gastrointestinal diseases, such as gastric mucosal damage caused by the combined action of acetic acid and alcohol. Overall, this study proposes an oral delivery system SP@ZnP for gastrointestinal infections therapy and their complication mitigation, which has great clinical application prospects.
Language: English
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W7237333344
FWCI:
Cites:
Cited by:
Related to: